




PHARMACEUTICAL 2019

Theravance Biopharma Inc.
Rank 100 of 363





RealRate

PHARMACEUTICAL 2019

Theravance Biopharma Inc. Rank 100 of 363



The relative strengths and weaknesses of Theravance Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Theravance Biopharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 176%, being 139% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	532,823
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	98,554
Liabilities, Non-Current	0
Other Assets	14,236
Other Compr. Net Income	567
Other Expenses	636
Other Liabilities	0
Other Net Income	23,148
Other Revenues	60,370
Property and Equipment	13,176
Research and Development	201,348
Selling, General and Administrative Expense	97,058

Output Variable	Value in 1000 USD
Assets	560,235
Liabilities	98,554
Expenses	299,042
Revenues	60,370
Stockholders Equity	461,681
Net Income	-215,524
Comprehensive Net Income	-215,240
Economic Capital Ratio	176%